260 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors.
Academia Sinica
Virtual screening identification of novel severe acute respiratory syndrome 3C-like protease inhibitors and in vitro confirmation.
Chonnam National University
Investigation of the pharmacophore space of Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) NTPase/helicase by dihydroxychromone derivatives.
Konkuk University
Aryl diketoacids (ADK) selectively inhibit duplex DNA-unwinding activity of SARS coronavirus NTPase/helicase.
Konkuk University
Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19.
Shanghai University of Traditional Chinese Medicine
Exploring 2-methyl-substituted vitamin K3 derivatives with potent inhibitory activity against the 3CL protease of SARS-CoV-2.
Shibaura Institute of Technology
Discovery of antiviral SARS-CoV-2 main protease inhibitors by structure-guided hit-to-lead optimization of carmofur.
Gwangju Institute of Science and Technology
Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.
Sichuan University
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors.
The State University of New Jersey
Spiroindole-containing compounds bearing phosphonate group of potential Mpro-SARS-CoV-2 inhibitory properties.
Augusta University
Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2.
Zhengzhou University
Thioamides in medicinal chemistry and as small molecule therapeutic agents.
University of Michigan
Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2.
University of Sharjah
N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease.
Univ. Lille
Nonpeptidic Irreversible Inhibitors of SARS-CoV-2 Main Protease with Potent Antiviral Activity.
University of Bonn
Machine learning-based QSAR and LB-PaCS-MD guided design of SARS-CoV-2 main protease inhibitors.
Chulalongkorn University
Novel Papain-Like Protease Inhibitors for Treating Viral Infections, in particular, Coronavirus Infections.
Smith, Gambrell & Russell
Development of novel antivrial agents that induce the degradation of the main protease of human-infecting coronaviruses.
Chinese Academy of Sciences
Synthesis, SARS-CoV-2 main protease inhibition, molecular docking and in silico ADME studies of furanochromene-quinoline hydrazone derivatives.
Susquehanna University
Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation.
Peking University
Non-Covalent Inhibitors of SARS-CoV-2 Papain-Like Protease (PLpro): In Vitro and In Vivo Antiviral Activity.
University of Arizona
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19.
Pfizer
Discovery of meisoindigo derivatives as noncovalent and orally available Mpro inhibitors: their therapeutic implications in the treatment of COVID-19.
Central South University
Exploiting high-energy hydration sites for the discovery of potent peptide aldehyde inhibitors of the SARS-CoV-2 main protease with cellular antiviral activity.
Takeda Development Center Americas, Inc
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.
Texas A&M University
Exploration of P1 and P4 modifications of nirmatrelvir: Design, synthesis, biological evaluation, and X-ray structural studies of SARS-CoV-2 Mpro inhibitors.
Purdue University
Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization.
University of Salerno
Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?
Ri.MED Foundation
Design, synthesis and biological evaluation of biaryl amide derivatives against SARS-CoV-2 with dual-target mechanism.
Chinese Academy of Medical Sciences and Peking Union Medical College
Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.
Baylor College of Medicine
Natural products as potential lead compounds to develop new antiviral drugs over the past decade.
Nanjing University of Chinese Medicine
Identification of SARS-CoV-2 Mpro inhibitors through deep reinforcement learning for de novo drug design and computational chemistry approaches.
Johannes Gutenberg University
SARS-CoV-2 Main Protease Inhibitors That Leverage Unique Interactions with the Solvent Exposed S3 Site of the Enzyme.
Texas A&M University
Metabolomic Analysis and Antiviral Screening of a Marine Algae Library Yield Jobosic Acid (2,5-Dimethyltetradecanoic Acid) as a Selective Inhibitor of SARS-CoV-2.
University of Puerto Rico-Medical Sciences Campus
An overview of anti-SARS-CoV-2 and anti-inflammatory potential of baicalein and its metabolite baicalin: Insights into molecular mechanisms.
Tripura University
Structure-based design of SARS-CoV-2 papain-like protease inhibitors.
State University of New Jersey
Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CLpro Inhibitors as anti-SARS-CoV-2 Drug Candidate.
University of Chinese Academy of Sciences
Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies.
Wichita State University
Macrocyclic Azapeptide Nitriles: Structure-Based Discovery of Potent SARS-CoV-2 Main Protease Inhibitors as Antiviral Drugs.
University of Bonn
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
Eberhard Karls University Tubingen
Design, synthesis, and biological evaluation of first-in-class indomethacin-based PROTACs degrading SARS-CoV-2 main protease and with broad-spectrum antiviral activity.
University of Perugia
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection.
Shaanxi University of Science & Technology
Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease.
Emory University
Click chemistry-aided drug discovery: A retrospective and prospective outlook.
Hangzhou Normal University
Plant-derived strategies to fight against severe acute respiratory syndrome coronavirus 2.
Zhengzhou University
Targeting SARS-CoV-2 entry processes: The promising potential and future of host-targeted small-molecule inhibitors.
National Clinical Research Center for Geriatrics
New Strategies for Responding to SARS-CoV-2: The Present and Future of Dual-Target Drugs.
China Pharmaceutical University
Design, Synthesis, and Biological Evaluation of 1,2,4-Oxadiazole Derivatives Containing an Aryl Carboxylic Acid Moiety as Potent Sarbecovirus Papain-like Protease Inhibitors.
Peking Union Medical College and Chinese Academy of Medical Sciences
Discovery of Anti-SARS-CoV-2 Nsp9 Binders from Natural Products by a Native Mass Spectrometry Approach.
Griffith University
Protease Inhibitors for Treating or Preventing Coronavirus Infection.
Smith, Gambrell & Russell
SARS-CoV-2 papain-like protease (PLpro) inhibitory and antiviral activity of small molecule derivatives for drug leads.
Purdue University
Cyclotheonellazoles D-I, Potent Elastase Inhibitory Thiazole-Containing Cyclic Peptides from
Griffith University
An ascidian Polycarpa aurata-derived pan-inhibitor against coronaviruses targeting M
Ocean University of China
Application and synthesis of thiazole ring in clinically approved drugs.
Zhengzhou University
Probing Ligand Binding Sites on Large Proteins by Nuclear Magnetic Resonance Spectroscopy of Genetically Encoded Non-Canonical Amino Acids.
Australian National University
Design, Synthesis, and Biological Evaluation of Trisubstituted Piperazine Derivatives as Noncovalent Severe Acute Respiratory Syndrome Coronavirus 2 Main Protease Inhibitors with Improved Antiviral Activity and Favorable Druggability.
Shandong University
Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19.
Smith, Gambrell & Russell
Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases.
University of Montpellier
Design and Optimization of Novel Competitive, Non-peptidic, SARS-CoV-2 M
Emory University
Structure-Activity Relationship Studies of SARS-CoV-2 Main Protease Inhibitors Containing 4-Fluorobenzothiazole-2-carbonyl Moieties.
Tokyo Medical and Dental University (TMDU)
Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease.
University of Southern California
Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease.
Sichuan University
A Systematic Survey of Reversibly Covalent Dipeptidyl Inhibitors of the SARS-CoV-2 Main Protease.
Texas A&M University
Broad-spectrum coronavirus 3C-like protease peptidomimetic inhibitors effectively block SARS-CoV-2 replication in cells: Design, synthesis, biological evaluation, and X-ray structure determination.
University of Naples Federico Ii
Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2.
National Research Centre
Development of a GC-376 Based Peptidomimetic PROTAC as a Degrader of 3-Chymotrypsin-like Protease of SARS-CoV-2.
University of Florence
Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential.
Alexandria University
Korupensamine A, but not its atropisomer, korupensamine B, inhibits SARS-CoV-2 in vitro by targeting its main protease (M
Nahda University
Discovery, synthesis and mechanism study of 2,3,5-substituted [1,2,4]-thiadiazoles as covalent inhibitors targeting 3C-Like protease of SARS-CoV-2.
Shanghaitech University
Deconvoluting low yield from weak potency in direct-to-biology workflows with machine learning.
University of Cambridge
-Arylsulfonamide-based adenosine analogues to target RNA cap
University of Montpellier Cnrs
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.
University of California San Francisco
Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead.
Calibr At Scripps Research Institute
Discovery of quinazolin-4-one-based non-covalent inhibitors targeting the severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2 M
China Pharmaceutical University
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022.
Shenyang Pharmaceutical University
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China.
Qufu Normal University
Novel dithiocarbamates selectively inhibit 3CL protease of SARS-CoV-2 and other coronaviruses.
Univ. Lille
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors.
University of Messina
Identification of Ebselen derivatives as novel SARS-CoV-2 main protease inhibitors: Design, synthesis, biological evaluation, and structure-activity relationships exploration.
Shandong University
Identification of novel 1,2,3-triazole isatin derivatives as potent SARS-CoV-2 3CLpro inhibitors
Shandong University
Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV).
Wichita State University
Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19.
University of Sharjah
Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group.
Shanghaitech University
Discovery of novel bicyclic[3.3.0]proline peptidyl α-ketoamides as potent 3CL-protease inhibitors for SARS-CoV-2.
Sun Yat-Sen University
Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery-Genetics Alliance Perspective.
University of Siena
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.
University of Oxford
Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety.
An Hui University of Traditional Chinese Medicine
Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors.
Sichuan University
Rational design of the zonulin inhibitor AT1001 derivatives as potential anti SARS-CoV-2.
European Biomedical Research Institute of Salerno (Ebris)
Fight against novel coronavirus: A perspective of medicinal chemists.
Jadavpur University
Identification of Natural Products Inhibiting SARS-CoV-2 by Targeting Viral Proteases: A Combined in Silico and in Vitro Approach.
University of Vienna
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
American University of Ras Al Khaimah
Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors.
Istituto Italiano Di Tecnologia
Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
University of Palermo
Structure-Guided Design of Potent Spirocyclic Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3C-like Protease.
Wichita State University
Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.
University of Oxford
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19.
Shionogi
In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease.
Shanghai Institute of Materia Medica
Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
Shanghai University of Traditional Chinese Medicine
Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
The University of Arizona
Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
China Pharmaceutical University
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
Shandong University
The Alpha Keto Amide Moiety as a Privileged Motif in Medicinal Chemistry: Current Insights and Emerging Opportunities.
Niddk
Novel Coronavirus Main Protease Di- and Tripeptide Inhibitors for Treating COVID-19.
Experimental Drug Development Centre
Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase.
University of Minnesota
Identification of Aloe-derived natural products as prospective lead scaffolds for SARS-CoV-2 main protease (M
University of Colorado
Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
Australian National University
The Natural Products Withaferin A and Withanone from the Medicinal Herb
Shiv Nadar University
A Warhead Substitution Study on the Coronavirus Main Protease Inhibitor Nirmatrelvir.
Experimental Drug Development Centre
Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir.
Texas A&M University
Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
Peking University
The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate.
Nankai University
Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease.
The State University of New Jersey
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
University of Naples "Federico Ii
Small-Molecule Thioesters as SARS-CoV-2 Main Protease Inhibitors: Enzyme Inhibition, Structure-Activity Relationships, Antiviral Activity, and X-ray Structure Determination.
Eberhard Karls University T£Bingen
Discovery of 2-Phenylquinolines with Broad-Spectrum Anti-coronavirus Activity.
University of Perugia
Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2.
Kunming Institute of Botany
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
Eberhard Karls University T£Bingen
Chemo- and Site-Selective Lysine Modification of Peptides and Proteins under Native Conditions Using the Water-Soluble Zolinium.
Chinese Academy of Sciences
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors.
University of Alberta Edmonton
Oral Nonpeptidic, Noncovalent Triazine Coronavirus Main Protease Inhibitors for Treating COVID-19.
Experimental Drug Development Centre
Tuaimenal A, a Meroterpene from the Irish Deep-Sea Soft Coral
University of South Florida
Discovery of potent benzoxaborole inhibitors against SARS-CoV-2 main and dengue virus proteases.
Heidelberg University
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Texas A&M University
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals.
Texas A&M University
Discovery of 2-thiobenzimidazoles as noncovalent inhibitors of SARS-CoV-2 main protease.
New York University Abu Dhabi
Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease.
Kyushu University
Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.
Bio-Techne (Tocris)
Chalcone-amide, a privileged backbone for the design and development of selective SARS-CoV/SARS-CoV-2 papain-like protease inhibitors.
Mazandaran University of Medical Sciences
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
Shandong University
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
University of California San Diego
Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Jadavpur University
Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
Peking Union Medical College
Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.
Bristol University
Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors.
Australian National University
Identification and design of novel small molecule inhibitors against MERS-CoV papain-like protease via high-throughput screening and molecular modeling.
University of Illinois At Chicago
Identification of novel drug scaffolds for inhibition of SARS-CoV 3-Chymotrypsin-like protease using virtual and high-throughput screenings.
University of Illinois At Chicago
Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors.
Tianjin University of Science and Technology
Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors.
Kansas State University
Dieckol, a SARS-CoV 3CL(pro) inhibitor, isolated from the edible brown algae Ecklonia cava.
Korea Research Institute of Bioscience and Biotechnology
Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases.
The Chinese University of Hong Kong
Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.
Academia Sinica
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CL(pro) inhibition.
Korea Research Institute of Bioscience and Biotechnology
SARS-CoV 3CLpro inhibitory effects of quinone-methide triterpenes from Tripterygium regelii.
Korea Research Institute of Bioscience and Biotechnology
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death.
National Human Genome Research Institute
New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.
Kyoto Pharmaceutical University
Novel small-molecule inhibitors of transmissible gastroenteritis virus.
National Health Research Institute
Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.
Purdue University
Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element.
Wichita State University
DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORS
Batterjee Medical College
TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
Genentech
ANTI-APOPTOTIC PROTEIN BCL-2 INHIBITOR, PHARMACEUTICAL COMPOSITION AND USES THEREOF
Hangzhou Healzen Therapeutics Co.
FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
Hangzhou Polymed Biopharmaceuticals
Benzodioxane modulators of leukotriene A4 hydrolase (LTA4H) for prevention and treatment of aging-associated diseases
Alkahest
PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN
Boehringer Ingelheim International
Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
Theravance Biopharma R&D Ip
Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
Ontario Institute For Cancer Research (Oicr)
Optically active crosslinked cyclic secondary amine derivative
Sumitomo Dainippon Pharma
Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors
Union Therapeutics
Selective androgen receptor degrader (SARD) ligands and methods of use thereof
University of Tennessee Research Foundation
Substituted tetrahydroquinolinone compounds as ROR gamma modulators
Aurigene Discovery Technologies
Functionalized pyrano[2,3-D]pyrimidin-7-one derivatives and methods for their preparation and use
Texas A&M University System
Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same
Sk Biopharmaceuticals
Substituted pyrimidines as cyclin-dependent kinase inhibitors
Shanghai Pharmaceuticals Holding
Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof
Japan Tobacco
Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
Enanta Pharmaceuticals
Imidazopyrazine compounds, preparation methods and uses thereof
Dongguan Zhenxing-Beite Medicine Technology
Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
Bristol-Myers Squibb
Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
Integrative Research Laboratories Sweden
Imidazole and triazole containing bicyclic compounds as JAK inhibitors
Theravance Biopharma R&D Ip
Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
Boehringer Ingelheim International
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
Forma Therapeutics
1,4,5-substituted 1,2,3-triazole analogues as antagonists of the pregnane X receptor
St. Jude Children''S Research Hospital
Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer
University of Pittsburgh
Benzimidazole-linked indole compound acting as novel divalent IAP antagonist
Medshine Discovery
1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
Incyte
Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
Je Il Pharmaceutical
Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists
Boehringer Ingelheim International
Novel inhibitors of HIV protease: design, synthesis and biological evaluation of picomolar inhibitors containing cyclic P1/P2 scaffolds.
Glaxosmithkline
Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease: secondary amide series.
Agouron Pharmaceuticals
Tyrosine kinase inhibitors. 6. Structure-activity relationships among N- and 3-substituted 2,2'-diselenobis(1H-indoles) for inhibition of protein tyrosine kinases and comparative in vitro and in vivo studies against selected sulfur congeners.
Parke-Davis Pharmaceutical Research
Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)- and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
University of Auckland